November 20, 2017

In Vivo

Proving the Value of Value-Based Deals

By Ed Silverman

As controversy continues over pharmaceutical pricing, more drugmakers are eyeing deals that peg health plan cost to outcomes to boost volume and win formulary placement. But these deals are challenging to construct and to date there is little evidence that they reduce costs for patients.

read full article >